FATE THERAPEUTICS INC (FATE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q3 '21: 54.7M Q4 '21: 55.8M Q1 '22: 63.1M Q2 '22: 68.3M Q3 '22: 69M Q4 '22: 96.3M Q1 '23: 136.9M Q2 '23: 119.2M Q3 '23: 106.2M Q4 '23: 63.5M Q1 '24: 6.5M Q2 '24: 12.3M Q3 '24: 13.4M Q4 '24: 13.6M Q1 '25: 13.3M Q2 '25: 8.5M Q3 '25: 7.1M Q4 '25: 6.6M Q1 '26: 6.3M Q2 '26: 6.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -181M Q4 '21: -217M Q1 '22: -245.3M Q2 '22: -281.6M Q3 '22: -313.3M Q4 '22: -308.4M Q1 '23: -262.5M Q2 '23: -242M Q3 '23: -206.9M Q4 '23: -190.5M Q1 '24: -213M Q2 '24: -195.5M Q3 '24: -196.6M Q4 '24: -210.3M Q1 '25: -200.5M Q2 '25: -192.4M Q3 '25: -174.7M Q4 '25: -147.7M Q1 '26: -139.4M Q2 '26: -133.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -196.6M Q4 '21: -212.2M Q1 '22: -232.8M Q2 '22: -253.7M Q3 '22: -294M Q4 '22: -281.7M Q1 '23: -234.9M Q2 '23: -211.6M Q3 '23: -173.2M Q4 '23: -160.9M Q1 '24: -190.1M Q2 '24: -175.7M Q3 '24: -178.2M Q4 '24: -186.3M Q1 '25: -175.9M Q2 '25: -171.5M Q3 '25: -156.1M Q4 '25: -136.3M Q1 '26: -129.9M Q2 '26: -126M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -113.2M Q4 '21: -162.9M Q1 '22: -200.4M Q2 '22: -221.4M Q3 '22: -243.1M Q4 '22: -248.2M Q1 '23: -212.5M Q2 '23: -187.8M Q3 '23: -171M Q4 '23: -132.3M Q1 '24: -136.8M Q2 '24: -140.6M Q3 '24: -131.7M Q4 '24: -122.9M Q1 '25: -123.3M Q2 '25: -115.6M Q3 '25: -110.6M Q4 '25: -106.1M Q1 '26: -103.1M Q2 '26: -101.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -147.8M Q4 '21: -213.6M Q1 '22: -257.2M Q2 '22: -274.8M Q3 '22: -290.4M Q4 '22: -283.8M Q1 '23: -241.1M Q2 '23: -208.5M Q3 '23: -183.7M Q4 '23: -138.4M Q1 '24: -139.8M Q2 '24: -141.4M Q3 '24: -132.5M Q4 '24: -123.6M Q1 '25: -125.2M Q2 '25: -118.8M Q3 '25: -115.4M Q4 '25: -112M Q1 '26: -108.1M Q2 '26: -105.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '21: 94.3M Q3 '21: 95.4M Q1 '22: 96.3M Q2 '22: 96.7M Q3 '22: 97M Q1 '23: 98.1M Q2 '23: 98.4M Q3 '23: 98.6M Q1 '24: 101.1M Q2 '24: 117.5M Q3 '24: 117.8M Q1 '25: 118.4M Q2 '25: 118.5M Q3 '25: 119M Q1 '26: 120M Q2 '26: 120.4M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -2.12 Q4 '21: -2.23 Q1 '22: -2.43 Q2 '22: -2.64 Q3 '22: -3.05 Q4 '22: -2.91 Q1 '23: -2.42 Q2 '23: -2.17 Q3 '23: -1.77 Q4 '23: -1.64 Q1 '24: -1.92 Q2 '24: -1.71 Q3 '24: -1.65 Q4 '24: -1.65 Q1 '25: -1.50 Q2 '25: -1.46 Q3 '25: -1.33 Q4 '25: -1.15 Q1 '26: -1.09 Q2 '26: -1.05 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.